1
|
Andreani GA, Mahmood S, Kua KL, Patel MS, Rideout TC. Influence of maternal α-lipoic acid supplementation in Sprague Dawley rats on maternal and fetal metabolic health in pregnancies complicated by obesity. J Nutr Biochem 2024:109731. [PMID: 39147245 DOI: 10.1016/j.jnutbio.2024.109731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2024] [Revised: 07/19/2024] [Accepted: 08/04/2024] [Indexed: 08/17/2024]
Abstract
The objective of this study was to investigate the influence of α-lipoic acid (LA; R enantiomer) supplementation on maternal and fetal metabolic health in pregnancies complicated by maternal obesity. Forty female Sprague-Dawley rats were randomized to one of four treatment groups (n=10/group) throughout pre-pregnancy (3 weeks) and gestation (20 days): (i) a low calorie control (CON); (ii) a high calorie obesity-inducing diet (HC); (iii) the HC diet with 0.25% LA (HC+LA) or; (iv) the HC diet pair-fed to match the caloric intake of the HC+LA group (HC+PF). On gestation day 20, pregnant rats were placed under anesthesia for collection of maternal/fetal blood and tissues. Compared with the HC group, LA-supplemented mothers demonstrated lower maternal pre-pregnancy and gestational weight gain (GWG), improved glycemic control (lower Homeostatic Model Assessment for Insulin Resistance), and higher cholesterol concentrations in serum [high-density lipoprotein cholesterol (HDL-C) and low-and very-low density lipoprotein cholesterol (LDL/VLDL) fractions] and liver. Male and female fetuses from LA-supplemented mothers exhibited lower body weight, improved insulin sensitivity, and evidence of altered lipid metabolism including lower serum HDL-C, lower serum triglyceride (TG), and increased hepatic TG accumulation. Although maternal LA supplementation showed some benefit for both mothers and fetuses with respect to obesity and glycemic control, concern about the potential longer-term implications of liver cholesterol (mothers) and TG accumulation (fetuses) needs further investigation.
Collapse
Affiliation(s)
- Gabriella A Andreani
- Departments of (a)Exercise and Nutrition Sciences, School of Public Health and Health Professions.
| | - Saleh Mahmood
- Departments of (a)Exercise and Nutrition Sciences, School of Public Health and Health Professions.
| | - Kok Lim Kua
- Department of Pediatrics, Center for Diabetes and Metabolic Disease, and Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, 46077, USA.
| | - Mulchand S Patel
- Biochemistry, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA 14214.
| | - Todd C Rideout
- Departments of (a)Exercise and Nutrition Sciences, School of Public Health and Health Professions.
| |
Collapse
|
2
|
Shipelin VA, Skiba EA, Budayeva VV, Shumakova AA, Kolobanov AI, Sokolov IE, Maisaya KZ, Guseva GV, Trusov NV, Masyutin AG, Delegan YA, Kocharovskaya YN, Bogun AG, Gmoshinski IV, Khotimchenko SA, Nikityuk DB. Toxicological Characteristics of Bacterial Nanocellulose in an In Vivo Experiment-Part 1: The Systemic Effects. NANOMATERIALS (BASEL, SWITZERLAND) 2024; 14:768. [PMID: 38727362 PMCID: PMC11085383 DOI: 10.3390/nano14090768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/12/2024] [Revised: 04/17/2024] [Accepted: 04/18/2024] [Indexed: 05/12/2024]
Abstract
Bacterial nanocellulose (BNC) is being considered as a potential replacement for microcrystalline cellulose as a food additive and a source of dietary fiber due to its unique properties. However, studies on the risks of consuming BNC in food are limited, and it is not yet approved for use in food in the US, EU, and Russia. AIM This study aims to perform a toxicological and hygienic assessment of the safety of BNC in a subacute 8-week administration in rats. METHODS BNC was administered to male Wistar rats in doses of 0, 1.0, 10.0, and 100 mg/kg body weight for 8 weeks. Various parameters such as anxiety levels, cognitive function, organ masses, blood serum and liver biochemistry, oxidative stress markers, vitamin levels, antioxidant gene expression, and liver and kidney histology were evaluated. RESULTS Low and medium doses of BNC increased anxiety levels and liver glutathione, while high doses led to elevated LDL cholesterol, creatinine, and uric acid levels. Liver tissue showed signs of degeneration at high doses. BNC did not significantly affect vitamin levels. CONCLUSION The adverse effects of BNC are either not dose-dependent or fall within normal physiological ranges. Any effects on rats are likely due to micronutrient deficiencies or impacts on intestinal microbiota.
Collapse
Affiliation(s)
- Vladimir A. Shipelin
- Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240 Moscow, Russia; (A.A.S.); (A.I.K.); (I.E.S.); (K.Z.M.); (N.V.T.); (I.V.G.); (S.A.K.); (D.B.N.)
- Academic Department of Innovational Materials and Technologies Chemistry, Plekhanov Russian University of Economics, 117997 Moscow, Russia
| | - Ekaterina A. Skiba
- Institute for Problems of Chemical and Energetic Technologies, Siberian Branch of the Russian Academy of Sciences, 659322 Biysk, Russia; (E.A.S.); (V.V.B.)
| | - Vera V. Budayeva
- Institute for Problems of Chemical and Energetic Technologies, Siberian Branch of the Russian Academy of Sciences, 659322 Biysk, Russia; (E.A.S.); (V.V.B.)
| | - Antonina A. Shumakova
- Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240 Moscow, Russia; (A.A.S.); (A.I.K.); (I.E.S.); (K.Z.M.); (N.V.T.); (I.V.G.); (S.A.K.); (D.B.N.)
| | - Alexey I. Kolobanov
- Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240 Moscow, Russia; (A.A.S.); (A.I.K.); (I.E.S.); (K.Z.M.); (N.V.T.); (I.V.G.); (S.A.K.); (D.B.N.)
| | - Ilya E. Sokolov
- Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240 Moscow, Russia; (A.A.S.); (A.I.K.); (I.E.S.); (K.Z.M.); (N.V.T.); (I.V.G.); (S.A.K.); (D.B.N.)
| | - Kirill Z. Maisaya
- Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240 Moscow, Russia; (A.A.S.); (A.I.K.); (I.E.S.); (K.Z.M.); (N.V.T.); (I.V.G.); (S.A.K.); (D.B.N.)
| | - Galina V. Guseva
- Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240 Moscow, Russia; (A.A.S.); (A.I.K.); (I.E.S.); (K.Z.M.); (N.V.T.); (I.V.G.); (S.A.K.); (D.B.N.)
| | - Nikita V. Trusov
- Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240 Moscow, Russia; (A.A.S.); (A.I.K.); (I.E.S.); (K.Z.M.); (N.V.T.); (I.V.G.); (S.A.K.); (D.B.N.)
| | | | - Yanina A. Delegan
- Institute of Biochemistry and Physiology of Microorganisms, Federal Research Center “Pushchino Scientific Center for Biological Research of Russian Academy of Sciences”, 142290 Pushchino, Russia; (Y.A.D.); (Y.N.K.)
| | - Yulia N. Kocharovskaya
- Institute of Biochemistry and Physiology of Microorganisms, Federal Research Center “Pushchino Scientific Center for Biological Research of Russian Academy of Sciences”, 142290 Pushchino, Russia; (Y.A.D.); (Y.N.K.)
| | - Alexander G. Bogun
- Institute of Biochemistry and Physiology of Microorganisms, Federal Research Center “Pushchino Scientific Center for Biological Research of Russian Academy of Sciences”, 142290 Pushchino, Russia; (Y.A.D.); (Y.N.K.)
| | - Ivan V. Gmoshinski
- Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240 Moscow, Russia; (A.A.S.); (A.I.K.); (I.E.S.); (K.Z.M.); (N.V.T.); (I.V.G.); (S.A.K.); (D.B.N.)
| | - Sergey A. Khotimchenko
- Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240 Moscow, Russia; (A.A.S.); (A.I.K.); (I.E.S.); (K.Z.M.); (N.V.T.); (I.V.G.); (S.A.K.); (D.B.N.)
- Department of Operative Surgery and Topographic Anatomy, I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia
| | - Dmitry B. Nikityuk
- Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240 Moscow, Russia; (A.A.S.); (A.I.K.); (I.E.S.); (K.Z.M.); (N.V.T.); (I.V.G.); (S.A.K.); (D.B.N.)
- Department of Operative Surgery and Topographic Anatomy, I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia
- Department of Ecology and Food Safety, Institute of Ecology, Patrice Lumumba Peoples’ Friendship University of Russia, 117198 Moscow, Russia
| |
Collapse
|
3
|
Abstract
Liver fibrosis has a high incidence worldwide and is the common pathological basis of many chronic liver diseases. Liver fibrosis is caused by the excessive deposition of extracellular matrix and concomitant collagen accumulation in livers and can lead to the development of liver cirrhosis and even liver cancer. A large number of studies have provided evidence that liver fibrosis can be blocked or even reversed by appropriate medical interventions. However, the antifibrosis drugs with ideal clinical efficacy are still insufficient. The edible plant-derived natural compounds have been reported to exert effective antifibrotic effects with few side-effects, representing a kind of promising source for the treatment of liver fibrosis. In this article, we reviewed the current progress of the natural compounds derived from dietary plants in the treatment of liver fibrosis, including phenolic compounds (capsaicin, chlorogenic acid, curcumin, ellagic acid, epigallocatechin-3-gallate, resveratrol, sinapic acid, syringic acid, vanillic acid and vitamin E), flavonoid compounds (genistein, hesperidin, hesperetin, naringenin, naringin and quercetin), sulfur-containing compounds (S-allylcysteine, ergothioneine, lipoic acid and sulforaphane) and other compounds (betaine, caffeine, cucurbitacin B, lycopene, α-mangostin, γ-mangostin, ursolic acid, vitamin C and yangonin). The pharmacological effects and related mechanisms of these compounds in in-vivo and in-vitro models of liver fibrosis are focused.
Collapse
|
4
|
The Prebiotic Potential of Geraniin and Geraniin-Enriched Extract against High-Fat-Diet-Induced Metabolic Syndrome in Sprague Dawley Rats. Antioxidants (Basel) 2022; 11:antiox11040632. [PMID: 35453317 PMCID: PMC9029067 DOI: 10.3390/antiox11040632] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 03/22/2022] [Accepted: 03/23/2022] [Indexed: 02/02/2023] Open
Abstract
Geraniin, an ellagitannin, has ameliorative properties against high-fat diet (HFD)-induced metabolic syndrome. Since geraniin has poor bioavailability, we hypothesised the interaction of this compound with gut microbiota as the main mechanism for improving metabolic aberrations. Male Sprague Dawley rats were divided into normal diet (ND)- and HFD-fed animals and treated with geraniin and an enriched extract of geraniin (GEE). We observed that 5 mg geraniin and 115 mg GEE supplementation significantly attenuated glucose intolerance, lipopolysaccharide-binding protein, total cholesterol, triacylglyceride, and low-density lipoprotein; improved insulin sensitivity; and significantly increased adiponectin and hepatic PPARα expression. Although geraniin and GEE did not significantly alter the gut microbial composition, we found an increment in the relative abundance of a few butyrate producers such as Alloprevotella, Blautia, Lachnospiraceae NK4A136 group, and Clostridium sensu stricto 1. Geraniin and its enriched extract’s ability to ameliorate metabolic syndrome parameters while positively affecting the growth of butyrate-producing bacteria suggests its potential prebiotic role.
Collapse
|